The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| INGN | -5.61% | -71.79% | -22.34% | -46% |
| S&P | +19.89% | +109.18% | +15.89% | +272% |
Inogen, Inc. is a medical technology company, which engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products include Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home. The company was founded by Alison Perry, Alison K. Bauerlein, Brenton Taylor, and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.
Big declines in stock price may bring big opportunities for patient investors.
Shares sink after the medical-device maker reported weak second-quarter results and slashed guidance. Again.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $92.28M | 4.0% |
| Gross Profit | $46.74M | -0.9% |
| Gross Margin | 50.65% | -2.5% |
| Market Cap | $189.02M | -1.4% |
| Market Cap / Employee | $0.25M | 0.0% |
| Employees | 766 | -8.2% |
| Net Income | -$4.15M | 25.7% |
| EBITDA | -$0.91M | -32.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $104.96M | 3.4% |
| Accounts Receivable | $38.59M | 7.1% |
| Inventory | 24.3 | 1.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $15.96M | -11.9% |
| Short Term Debt | $3.08M | -7.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -8.39% | 18.7% |
| Return On Invested Capital | -18.88% | -5.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $0.48M | -87.4% |
| Operating Free Cash Flow | $4.35M | -35.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.23 | 1.18 | 0.98 | 0.95 | -4.28% |
| Price to Sales | 0.69 | 0.65 | 0.53 | 0.55 | -6.11% |
| Price to Tangible Book Value | 1.59 | 1.54 | 1.27 | 1.21 | -5.88% |
| Enterprise Value to EBITDA | -74.24 | -23.49 | -30.85 | -92.97 | -30.41% |
| Return on Equity | -25.3% | -19.0% | -14.1% | -13.5% | -66.34% |
| Total Debt | $20.15M | $19.41M | $19.21M | $19.04M | -11.20% |
INGN earnings call for the period ending September 30, 2021.
INGN earnings call for the period ending June 30, 2021.
INGN earnings call for the period ending March 31, 2021.
INGN earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
